Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by DnB Asset Management AS

DnB Asset Management AS raised its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 1.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,690 shares of the medical research company’s stock after acquiring an additional 124 shares during the quarter. DnB Asset Management AS’s holdings in Charles River Laboratories International were worth $1,604,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Charles River Laboratories International by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company’s stock worth $1,136,938,000 after buying an additional 60,497 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Charles River Laboratories International by 135,927.9% in the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock worth $736,819,000 after acquiring an additional 3,738,018 shares during the period. State Street Corp boosted its stake in shares of Charles River Laboratories International by 2.0% during the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after acquiring an additional 41,421 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of Charles River Laboratories International by 2.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock valued at $330,231,000 after acquiring an additional 47,221 shares during the period. Finally, Sei Investments Co. increased its stake in shares of Charles River Laboratories International by 6.1% in the 4th quarter. Sei Investments Co. now owns 673,868 shares of the medical research company’s stock valued at $124,394,000 after purchasing an additional 38,827 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Down 3.1 %

Shares of NYSE:CRL opened at $145.82 on Wednesday. Charles River Laboratories International, Inc. has a 52-week low of $145.66 and a 52-week high of $267.83. The stock has a market cap of $7.46 billion, a P/E ratio of 972.11, a PEG ratio of 4.54 and a beta of 1.45. The business has a fifty day moving average of $163.95 and a two-hundred day moving average of $181.92. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. During the same period last year, the business earned $2.46 earnings per share. Charles River Laboratories International’s revenue was down 1.1% compared to the same quarter last year. On average, research analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of the company’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the transaction, the executive vice president now owns 20,013 shares of the company’s stock, valued at $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO James C. Foster purchased 6,075 shares of the company’s stock in a transaction on Thursday, February 20th. The shares were bought at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the transaction, the chief executive officer now owns 183,639 shares of the company’s stock, valued at approximately $30,302,271.39. The trade was a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 1.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on CRL. William Blair lowered Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. JPMorgan Chase & Co. reduced their price objective on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a research report on Thursday, February 20th. Morgan Stanley dropped their target price on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 5th. Barclays reduced their price target on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 18th. Finally, Redburn Atlantic upgraded Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price objective on the stock in a report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company’s stock. According to data from MarketBeat, Charles River Laboratories International presently has an average rating of “Hold” and a consensus target price of $189.77.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).